Premature ventricular contraction interventions: Difference between revisions

Jump to navigation Jump to search
VisualWikitext
(/* 2017 AHA/ACC/HRS Guideline for Management of Patients with Ventricular Arrhythmias and the Prevention of Sudden Cardiac Death (DO NOT EDIT){{cite journal|last1=Al-Khatib|first1=Sana M.|last2=Stevenson|first2=William G.|last3=Ackerman|first3=Michael...)
Line 41: Line 41:
|-
|-
|bgcolor="LemonChiffon" |<nowiki></nowiki>'''1.'''  In [[patients]] with [[Ventricular tachycardia|VT]]/[[Ventricular fibrillation|VF]] storm in whom a [[beta blocker]], other [[antiarrhythmic medications]], and [[catheter ablation]] are ineffective, not tolerated, or not possible, [[cardiac]] sympathetic denervation may be reasonable ''([[ACC AHA Guidelines Classification Scheme#Level of Evidence|Level of Evidence: C-LD]]).''<ref name="VaseghiBarwad2017">{{cite journal|last1=Vaseghi|first1=Marmar|last2=Barwad|first2=Parag|last3=Malavassi Corrales|first3=Federico J.|last4=Tandri|first4=Harikrishna|last5=Mathuria|first5=Nilesh|last6=Shah|first6=Rushil|last7=Sorg|first7=Julie M.|last8=Gima|first8=Jean|last9=Mandal|first9=Kaushik|last10=Sàenz Morales|first10=Luis C.|last11=Lokhandwala|first11=Yash|last12=Shivkumar|first12=Kalyanam|title=Cardiac Sympathetic Denervation for Refractory Ventricular Arrhythmias|journal=Journal of the American College of Cardiology|volume=69|issue=25|year=2017|pages=3070–3080|issn=07351097|doi=10.1016/j.jacc.2017.04.035}}</ref><ref name="VaseghiGima2014">{{cite journal|last1=Vaseghi|first1=Marmar|last2=Gima|first2=Jean|last3=Kanaan|first3=Christopher|last4=Ajijola|first4=Olujimi A.|last5=Marmureanu|first5=Alexander|last6=Mahajan|first6=Aman|last7=Shivkumar|first7=Kalyanam|title=Cardiac sympathetic denervation in patients with refractory ventricular arrhythmias or electrical storm: Intermediate and long-term follow-up|journal=Heart Rhythm|volume=11|issue=3|year=2014|pages=360–366|issn=15475271|doi=10.1016/j.hrthm.2013.11.028}}</ref><ref name="SchwartzMotolese1992">{{cite journal|last1=Schwartz|first1=Peter J.|last2=Motolese|first2=Mario|last3=Pollavini|first3=Giorgio|last4=Lotto|first4=Antonio|last5=Ruberti|first5=Ugo|last6=Trazzi|first6=Rinaldo|last7=Bartorelli|first7=Cesare|last8=Zanchetti|first8=Alberto|last9=Group|first9=The Italian Sudden Death Prevention|title=Prevention of Sudden Cardiac Death After a First Myocardial Infarction by Pharmacologic or Surgical Antiadrenergic Interventions|journal=Journal of Cardiovascular Electrophysiology|volume=3|issue=1|year=1992|pages=2–16|issn=1045-3873|doi=10.1111/j.1540-8167.1992.tb01090.x}}</ref><nowiki/>
|bgcolor="LemonChiffon" |<nowiki></nowiki>'''1.'''  In [[patients]] with [[Ventricular tachycardia|VT]]/[[Ventricular fibrillation|VF]] storm in whom a [[beta blocker]], other [[antiarrhythmic medications]], and [[catheter ablation]] are ineffective, not tolerated, or not possible, [[cardiac]] sympathetic denervation may be reasonable ''([[ACC AHA Guidelines Classification Scheme#Level of Evidence|Level of Evidence: C-LD]]).''<ref name="VaseghiBarwad2017">{{cite journal|last1=Vaseghi|first1=Marmar|last2=Barwad|first2=Parag|last3=Malavassi Corrales|first3=Federico J.|last4=Tandri|first4=Harikrishna|last5=Mathuria|first5=Nilesh|last6=Shah|first6=Rushil|last7=Sorg|first7=Julie M.|last8=Gima|first8=Jean|last9=Mandal|first9=Kaushik|last10=Sàenz Morales|first10=Luis C.|last11=Lokhandwala|first11=Yash|last12=Shivkumar|first12=Kalyanam|title=Cardiac Sympathetic Denervation for Refractory Ventricular Arrhythmias|journal=Journal of the American College of Cardiology|volume=69|issue=25|year=2017|pages=3070–3080|issn=07351097|doi=10.1016/j.jacc.2017.04.035}}</ref><ref name="VaseghiGima2014">{{cite journal|last1=Vaseghi|first1=Marmar|last2=Gima|first2=Jean|last3=Kanaan|first3=Christopher|last4=Ajijola|first4=Olujimi A.|last5=Marmureanu|first5=Alexander|last6=Mahajan|first6=Aman|last7=Shivkumar|first7=Kalyanam|title=Cardiac sympathetic denervation in patients with refractory ventricular arrhythmias or electrical storm: Intermediate and long-term follow-up|journal=Heart Rhythm|volume=11|issue=3|year=2014|pages=360–366|issn=15475271|doi=10.1016/j.hrthm.2013.11.028}}</ref><ref name="SchwartzMotolese1992">{{cite journal|last1=Schwartz|first1=Peter J.|last2=Motolese|first2=Mario|last3=Pollavini|first3=Giorgio|last4=Lotto|first4=Antonio|last5=Ruberti|first5=Ugo|last6=Trazzi|first6=Rinaldo|last7=Bartorelli|first7=Cesare|last8=Zanchetti|first8=Alberto|last9=Group|first9=The Italian Sudden Death Prevention|title=Prevention of Sudden Cardiac Death After a First Myocardial Infarction by Pharmacologic or Surgical Antiadrenergic Interventions|journal=Journal of Cardiovascular Electrophysiology|volume=3|issue=1|year=1992|pages=2–16|issn=1045-3873|doi=10.1111/j.1540-8167.1992.tb01090.x}}</ref><nowiki/>
|-
|}
===Recommendations for Management of Cardiac Arrest===
{|class="wikitable"
|-
| colspan="1" style="text-align:center; background:LightGreen"|[[ESC Guidelines Classification Scheme#Classification of Recommendations|Class I]]
|-
| bgcolor="LightGreen"|<nowiki></nowiki>'''1.'''  In [[patients]] with [[HFrEF]] ([[LVEF]] ≤40%), [[Therapy|treatment]] with a [[beta blocker]], a [[Mineralocorticoid receptor|mineralocorticoid receptor antagonist]] and either an [[angiotensin-converting enzyme inhibitor]], an [[Angiotensin receptor blocker|angiotensin-receptor blocker]], or an [[angiotensin receptor]]-[[neprilysin]] inhibitor is recommended to reduce [[SCD]] and all-cause [[mortality]] ''([[ACC AHA Guidelines Classification Scheme#Level of Evidence|Level of Evidence: A]])''.<ref name="YancyJessup2016">{{cite journal|last1=Yancy|first1=Clyde W.|last2=Jessup|first2=Mariell|last3=Bozkurt|first3=Biykem|last4=Butler|first4=Javed|last5=Casey|first5=Donald E.|last6=Colvin|first6=Monica M.|last7=Drazner|first7=Mark H.|last8=Filippatos|first8=Gerasimos|last9=Fonarow|first9=Gregg C.|last10=Givertz|first10=Michael M.|last11=Hollenberg|first11=Steven M.|last12=Lindenfeld|first12=JoAnn|last13=Masoudi|first13=Frederick A.|last14=McBride|first14=Patrick E.|last15=Peterson|first15=Pamela N.|last16=Stevenson|first16=Lynne Warner|last17=Westlake|first17=Cheryl|title=2016 ACC/AHA/HFSA Focused Update on New Pharmacological Therapy for Heart Failure: An Update of the 2013 ACCF/AHA Guideline for the Management of Heart Failure: A Report of the American College of Cardiology/American Heart Association Task Force on Clinical Practice Guidelines and the Heart Failure Society of America|journal=Circulation|volume=134|issue=13|year=2016|issn=0009-7322|doi=10.1161/CIR.0000000000000435}}</ref><ref>{{Cite journal
| title = The Cardiac Insufficiency Bisoprolol Study II (CIBIS-II): a randomised trial
| journal = [[Lancet (London, England)]]
| volume = 353
| issue = 9146
| pages = 9–13
| year = 1999
| month = January
| pmid = 10023943
}}</ref><ref name="CohnJohnson1991">{{cite journal|last1=Cohn|first1=Jay N.|last2=Johnson|first2=Gary|last3=Ziesche|first3=Susan|last4=Cobb|first4=Frederick|last5=Francis|first5=Gary|last6=Tristani|first6=Felix|last7=Smith|first7=Raphael|last8=Dunkman|first8=W. Bruce|last9=Loeb|first9=Henry|last10=Wong|first10=Maylene|last11=Bhat|first11=Geetha|last12=Goldman|first12=Steven|last13=Fletcher|first13=Ross D.|last14=Doherty|first14=James|last15=Hughes|first15=C. Vincent|last16=Carson|first16=Peter|last17=Cintron|first17=Guillermo|last18=Shabetai|first18=Ralph|last19=Haakenson|first19=Clair|title=A Comparison of Enalapril with Hydralazine–Isosorbide Dinitrate in the Treatment of Chronic Congestive Heart Failure|journal=New England Journal of Medicine|volume=325|issue=5|year=1991|pages=303–310|issn=0028-4793|doi=10.1056/NEJM199108013250502}}</ref><ref name="PackerBristow1996">{{cite journal|last1=Packer|first1=Milton|last2=Bristow|first2=Michael R.|last3=Cohn|first3=Jay N.|last4=Colucci|first4=Wilson S.|last5=Fowler|first5=Michael B.|last6=Gilbert|first6=Edward M.|last7=Shusterman|first7=Neil H.|title=The Effect of Carvedilol on Morbidity and Mortality in Patients with Chronic Heart Failure|journal=New England Journal of Medicine|volume=334|issue=21|year=1996|pages=1349–1355|issn=0028-4793|doi=10.1056/NEJM199605233342101}}</ref><ref>{{cite journal|title=Effect of carvedilol on outcome after myocardial infarction in patients with left-ventricular dysfunction: the CAPRICORN randomised trial|journal=The Lancet|volume=357|issue=9266|year=2001|pages=1385–1390|issn=01406736|doi=10.1016/S0140-6736(00)04560-8}}</ref><ref name="PittRemme2003">{{cite journal|last1=Pitt|first1=Bertram|last2=Remme|first2=Willem|last3=Zannad|first3=Faiez|last4=Neaton|first4=James|last5=Martinez|first5=Felipe|last6=Roniker|first6=Barbara|last7=Bittman|first7=Richard|last8=Hurley|first8=Steve|last9=Kleiman|first9=Jay|last10=Gatlin|first10=Marjorie|title=Eplerenone, a Selective Aldosterone Blocker, in Patients with Left Ventricular Dysfunction after Myocardial Infarction|journal=New England Journal of Medicine|volume=348|issue=14|year=2003|pages=1309–1321|issn=0028-4793|doi=10.1056/NEJMoa030207}}</ref><ref name="Al Chekakie2013">{{cite journal|last1=Al Chekakie|first1=M. Obadah|title=Traditional Heart Failure Medications and Sudden Cardiac Death Prevention|journal=Journal of Cardiovascular Pharmacology and Therapeutics|volume=18|issue=5|year=2013|pages=412–426|issn=1074-2484|doi=10.1177/1074248413491496}}</ref><ref name="PfefferMcMurray2003">{{cite journal|last1=Pfeffer|first1=Marc A.|last2=McMurray|first2=John J.V.|last3=Velazquez|first3=Eric J.|last4=Rouleau|first4=Jean-Lucien|last5=Køber|first5=Lars|last6=Maggioni|first6=Aldo P.|last7=Solomon|first7=Scott D.|last8=Swedberg|first8=Karl|last9=Van de Werf|first9=Frans|last10=White|first10=Harvey|last11=Leimberger|first11=Jeffrey D.|last12=Henis|first12=Marc|last13=Edwards|first13=Susan|last14=Zelenkofske|first14=Steven|last15=Sellers|first15=Mary Ann|last16=Califf|first16=Robert M.|title=Valsartan, Captopril, or Both in Myocardial Infarction Complicated by Heart Failure, Left Ventricular Dysfunction, or Both|journal=New England Journal of Medicine|volume=349|issue=20|year=2003|pages=1893–1906|issn=0028-4793|doi=10.1056/NEJMoa032292}}</ref><nowiki/>
|-
|-
|}
|}

Revision as of 14:27, 23 April 2020

Premature ventricular contraction Microchapters

Home

Patient Information

Overview

Historical Perspective

Classification

Pathophysiology

Causes

Differentiating Premature Ventricular Contraction from other Disorders

Epidemiology and Demographics

Risk Factors

Screening

Natural History, Complications and Prognosis

Diagnosis

Diagnostic Study of Choice

History and Symptoms

Physical Examination

Laboratory Findings

Electrocardiogram

X-ray

Echocardiography and Ultrasound

CT scan

MRI

Other Imaging Findings

Other Diagnostic Studies

Treatment

Medical Therapy

Interventions

Surgery

Primary Prevention

Secondary Prevention

Cost-Effectiveness of Therapy

Future or Investigational Therapies

Case Studies

Case #1

Premature ventricular contraction interventions On the Web

Most recent articles

Most cited articles

Review articles

CME Programs

Powerpoint slides

Images

Ongoing Trials at Clinical Trials.gov

US National Guidelines Clearinghouse

NICE Guidance

FDA on Premature ventricular contraction interventions

CDC onPremature ventricular contraction interventions

Premature ventricular contraction interventions in the news

Blogs on Premature ventricular contraction interventions

to Hospitals Treating Premature ventricular contraction interventions

Risk calculators and risk factors for Premature ventricular contraction interventions

Editor-In-Chief: C. Michael Gibson, M.S., M.D. [1]; Associate Editor(s)-in-Chief: Homa Najafi, M.D.[2]Mugilan Poongkunran M.B.B.S [3]

Overview

There are no recommended therapeutic interventions for the management of [disease name].

OR

[name of intervention] is not the first-line treatment option for patients with [disease name]. [name of intervention] is usually reserved for patients with either [indication 1], [indication 2], and/or [indication 3].

OR

The mainstay of treatment for [disease name] is medical therapy/surgery. [Name of intervention] is usually reserved for patients with either [indication 1], [indication 2], and/or [indication 3].

OR

The feasibility of [name of intervention] depends on the stage of [disease or malignancy] at the time of diagnosis.

OR

[Name of intervention] is the mainstay of treatment for [disease or malignancy].

Indications

The mainstay of treatment for TT is medical therapy.

Overview

Radiofrequency ablation is useful for treating patients with high frequency of premature ventricular contraction episodes.

Ablation

Recent studies have shown that those subjects who have an extremely high occurrence of PVCs (several thousand a day) can develop dilated cardiomyopathy. In these cases, if the PVCs are reduced or removed by ablation therapy, the cardiomyopathy usually regresses.[1][2]

2017 AHA/ACC/HRS Guideline for Management of Patients with Ventricular Arrhythmias and the Prevention of Sudden Cardiac Death (DO NOT EDIT)[3]

Recommendations for Autonomic Modulation

Class IIb
1. In patients with VT/VF storm in whom a beta blocker, other antiarrhythmic medications, and catheter ablation are ineffective, not tolerated, or not possible, cardiac sympathetic denervation may be reasonable (Level of Evidence: C-LD).[4][5][6]

Recommendations for Management of Cardiac Arrest

Class I
1. In patients with HFrEF (LVEF ≤40%), treatment with a beta blocker, a mineralocorticoid receptor antagonist and either an angiotensin-converting enzyme inhibitor, an angiotensin-receptor blocker, or an angiotensin receptor-neprilysin inhibitor is recommended to reduce SCD and all-cause mortality (Level of Evidence: A).[7][8][9][10][11][12][13][14]

References

  1. ↑ Belhassen B (2005), "Radiofrequency ablation of "benign" right ventricular outflow tract extrasystoles: a therapy that has found its disease? In patients with no known coronary artery disease (CAD), the presence of frequent premature ventricular contractions (PVCs) is linked to acute myocardial infarction and sudden death. The Framingham Heart Study defines frequent as >30 PVCs per hour. The American College of Cardiology and the American Heart Association recommend evaluation for CAD in patients who have frequent PVCs and cardiac risk factors, such as hypertension and smoking (SOR C). Evaluation for CAD may include stress testing, echocardiography, and ambulatory rhythm monitoring", J. Am. Coll. Cardiol., 45 (8): 1266–8, doi:10.1016/j.jacc.2005.01.028, PMID 15837260 Unknown parameter |month= ignored (help)
  2. ↑ Shiraishi, Hirokazu; Ishibashi, Kazuya; Urao, Norifumi; Tsukamoto, Masaki; Hyogo, Masayuki; Keira, Natsuya; Hirasaki, Satoshi; Shirayama, Takeshi; Nakagawa, Masao (2002), "A case of cardiomyopathy induced by premature ventricular complexes", Circulation, 66 (11): 1065–7, doi:10.1253/circj.66.1065
  3. ↑ Al-Khatib, Sana M.; Stevenson, William G.; Ackerman, Michael J.; Bryant, William J.; Callans, David J.; Curtis, Anne B.; Deal, Barbara J.; Dickfeld, Timm; Field, Michael E.; Fonarow, Gregg C.; Gillis, Anne M.; Granger, Christopher B.; Hammill, Stephen C.; Hlatky, Mark A.; Joglar, José A.; Kay, G. Neal; Matlock, Daniel D.; Myerburg, Robert J.; Page, Richard L. (2018). "2017 AHA/ACC/HRS Guideline for Management of Patients With Ventricular Arrhythmias and the Prevention of Sudden Cardiac Death". Circulation. 138 (13). doi:10.1161/CIR.0000000000000549. ISSN 0009-7322.
  4. ↑ Vaseghi, Marmar; Barwad, Parag; Malavassi Corrales, Federico J.; Tandri, Harikrishna; Mathuria, Nilesh; Shah, Rushil; Sorg, Julie M.; Gima, Jean; Mandal, Kaushik; Sàenz Morales, Luis C.; Lokhandwala, Yash; Shivkumar, Kalyanam (2017). "Cardiac Sympathetic Denervation for Refractory Ventricular Arrhythmias". Journal of the American College of Cardiology. 69 (25): 3070–3080. doi:10.1016/j.jacc.2017.04.035. ISSN 0735-1097.
  5. ↑ Vaseghi, Marmar; Gima, Jean; Kanaan, Christopher; Ajijola, Olujimi A.; Marmureanu, Alexander; Mahajan, Aman; Shivkumar, Kalyanam (2014). "Cardiac sympathetic denervation in patients with refractory ventricular arrhythmias or electrical storm: Intermediate and long-term follow-up". Heart Rhythm. 11 (3): 360–366. doi:10.1016/j.hrthm.2013.11.028. ISSN 1547-5271.
  6. ↑ Schwartz, Peter J.; Motolese, Mario; Pollavini, Giorgio; Lotto, Antonio; Ruberti, Ugo; Trazzi, Rinaldo; Bartorelli, Cesare; Zanchetti, Alberto; Group, The Italian Sudden Death Prevention (1992). "Prevention of Sudden Cardiac Death After a First Myocardial Infarction by Pharmacologic or Surgical Antiadrenergic Interventions". Journal of Cardiovascular Electrophysiology. 3 (1): 2–16. doi:10.1111/j.1540-8167.1992.tb01090.x. ISSN 1045-3873.
  7. ↑ Yancy, Clyde W.; Jessup, Mariell; Bozkurt, Biykem; Butler, Javed; Casey, Donald E.; Colvin, Monica M.; Drazner, Mark H.; Filippatos, Gerasimos; Fonarow, Gregg C.; Givertz, Michael M.; Hollenberg, Steven M.; Lindenfeld, JoAnn; Masoudi, Frederick A.; McBride, Patrick E.; Peterson, Pamela N.; Stevenson, Lynne Warner; Westlake, Cheryl (2016). "2016 ACC/AHA/HFSA Focused Update on New Pharmacological Therapy for Heart Failure: An Update of the 2013 ACCF/AHA Guideline for the Management of Heart Failure: A Report of the American College of Cardiology/American Heart Association Task Force on Clinical Practice Guidelines and the Heart Failure Society of America". Circulation. 134 (13). doi:10.1161/CIR.0000000000000435. ISSN 0009-7322.
  8. ↑ "The Cardiac Insufficiency Bisoprolol Study II (CIBIS-II): a randomised trial". Lancet (London, England). 353 (9146): 9–13. 1999. PMID 10023943. Unknown parameter |month= ignored (help)
  9. ↑ Cohn, Jay N.; Johnson, Gary; Ziesche, Susan; Cobb, Frederick; Francis, Gary; Tristani, Felix; Smith, Raphael; Dunkman, W. Bruce; Loeb, Henry; Wong, Maylene; Bhat, Geetha; Goldman, Steven; Fletcher, Ross D.; Doherty, James; Hughes, C. Vincent; Carson, Peter; Cintron, Guillermo; Shabetai, Ralph; Haakenson, Clair (1991). "A Comparison of Enalapril with Hydralazine–Isosorbide Dinitrate in the Treatment of Chronic Congestive Heart Failure". New England Journal of Medicine. 325 (5): 303–310. doi:10.1056/NEJM199108013250502. ISSN 0028-4793.
  10. ↑ Packer, Milton; Bristow, Michael R.; Cohn, Jay N.; Colucci, Wilson S.; Fowler, Michael B.; Gilbert, Edward M.; Shusterman, Neil H. (1996). "The Effect of Carvedilol on Morbidity and Mortality in Patients with Chronic Heart Failure". New England Journal of Medicine. 334 (21): 1349–1355. doi:10.1056/NEJM199605233342101. ISSN 0028-4793.
  11. ↑ "Effect of carvedilol on outcome after myocardial infarction in patients with left-ventricular dysfunction: the CAPRICORN randomised trial". The Lancet. 357 (9266): 1385–1390. 2001. doi:10.1016/S0140-6736(00)04560-8. ISSN 0140-6736.
  12. ↑ Pitt, Bertram; Remme, Willem; Zannad, Faiez; Neaton, James; Martinez, Felipe; Roniker, Barbara; Bittman, Richard; Hurley, Steve; Kleiman, Jay; Gatlin, Marjorie (2003). "Eplerenone, a Selective Aldosterone Blocker, in Patients with Left Ventricular Dysfunction after Myocardial Infarction". New England Journal of Medicine. 348 (14): 1309–1321. doi:10.1056/NEJMoa030207. ISSN 0028-4793.
  13. ↑ Al Chekakie, M. Obadah (2013). "Traditional Heart Failure Medications and Sudden Cardiac Death Prevention". Journal of Cardiovascular Pharmacology and Therapeutics. 18 (5): 412–426. doi:10.1177/1074248413491496. ISSN 1074-2484.
  14. ↑ Pfeffer, Marc A.; McMurray, John J.V.; Velazquez, Eric J.; Rouleau, Jean-Lucien; Køber, Lars; Maggioni, Aldo P.; Solomon, Scott D.; Swedberg, Karl; Van de Werf, Frans; White, Harvey; Leimberger, Jeffrey D.; Henis, Marc; Edwards, Susan; Zelenkofske, Steven; Sellers, Mary Ann; Califf, Robert M. (2003). "Valsartan, Captopril, or Both in Myocardial Infarction Complicated by Heart Failure, Left Ventricular Dysfunction, or Both". New England Journal of Medicine. 349 (20): 1893–1906. doi:10.1056/NEJMoa032292. ISSN 0028-4793.

Template:WH Template:WS]

Retrieved from "https://www.wikidoc.org/index.php?title=Premature_ventricular_contraction_interventions&oldid=1606015"